Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Director William R. Ringo sold 1,800 shares of Five Prime Therapeutics stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $40.26, for a total value of $72,468.00. Following the sale, the director now directly owns 1,200 shares in the company, valued at $48,312. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Five Prime Therapeutics, Inc. (NASDAQ FPRX) traded down 5.21% during mid-day trading on Tuesday, reaching $38.19. 335,684 shares of the company’s stock traded hands. The stock’s market cap is $1.07 billion. The firm has a 50 day moving average price of $33.83 and a 200-day moving average price of $31.79. Five Prime Therapeutics, Inc. has a 12 month low of $25.97 and a 12 month high of $60.98.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.43). Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The company had revenue of $7.80 million for the quarter, compared to the consensus estimate of $8.32 million. During the same quarter last year, the business earned ($0.49) EPS. Five Prime Therapeutics’s revenue was down 16.1% on a year-over-year basis. On average, analysts predict that Five Prime Therapeutics, Inc. will post ($5.29) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Five Prime Therapeutics, Inc. (FPRX) Director Sells $72,468.00 in Stock” was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/10/03/five-prime-therapeutics-inc-fprx-director-sells-72468-00-in-stock.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in FPRX. Rockefeller Financial Services Inc. bought a new position in shares of Five Prime Therapeutics in the second quarter worth $210,000. Alliancebernstein L.P. lifted its position in Five Prime Therapeutics by 9.2% during the first quarter. Alliancebernstein L.P. now owns 97,770 shares of the biotechnology company’s stock worth $3,534,000 after purchasing an additional 8,220 shares during the period. Goldman Sachs Group Inc. lifted its position in Five Prime Therapeutics by 142.2% during the first quarter. Goldman Sachs Group Inc. now owns 217,462 shares of the biotechnology company’s stock worth $7,861,000 after purchasing an additional 127,693 shares during the period. Marshall Wace North America L.P. lifted its position in Five Prime Therapeutics by 19.6% during the second quarter. Marshall Wace North America L.P. now owns 341,387 shares of the biotechnology company’s stock worth $10,241,000 after purchasing an additional 56,058 shares during the period. Finally, AXA lifted its position in Five Prime Therapeutics by 77.0% during the first quarter. AXA now owns 15,400 shares of the biotechnology company’s stock worth $557,000 after purchasing an additional 6,700 shares during the period. 84.05% of the stock is currently owned by institutional investors.

FPRX has been the subject of a number of recent research reports. Jefferies Group LLC reissued a “buy” rating and issued a $52.00 target price on shares of Five Prime Therapeutics in a report on Tuesday, September 12th. BMO Capital Markets restated a “hold” rating and set a $39.00 target price on shares of Five Prime Therapeutics in a research report on Friday, September 22nd. Royal Bank Of Canada began coverage on Five Prime Therapeutics in a research note on Thursday, September 14th. They issued an “outperform” rating and a $41.00 price target on the stock. ValuEngine raised Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, BidaskClub cut Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $54.86.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Insider Buying and Selling by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.